INTERVENTIONS FOR STRUCTURAL HEART DISEASE

CoreValve implantation for severe aortic regurgitation: a multicentre registry

EuroIntervention 2014;10:739-745. DOI: 10.4244/EIJV10I6A127

Luca Testa
Luca Testa1*, MD, PhD; Azeem Latib2, MD; Marco Luciano Rossi3, MD; Federico De Marco4, MD; Marco De Carlo5, MD; Claudia Fiorina6, MD; Jacopo Oreglia4, MD; Anna Sonia Petronio5, MD; Federica Ettori6, MD; Stefano De Servi7, MD; Silvio Klugmann4, MD; Gian Paolo Ussia8, MD; Corrado Tamburino8, MD; Paolo Panisi1, MD; Nedy Brambilla<span class="e
1. Istituto Clinico S. Ambrogio, Milan, Italy; 2. San Raffaele Hospital and EMO-GVM Centro Cuore Columbus, Milan, Italy; 3. Istituto Clinico Humanitas, Rozzano, Italy; 4. Niguarda Ca Granda Hospital, Milan, Italy; 5. Azienda Ospedaliero-Universitaria Pisa

Aims: We sought to evaluate the outcome of transcatheter aortic valve replacement (TAVR) with the CoreValve Revalving System (CRS-TAVR) in inoperable patients presenting with severe aortic regurgitation (AR), compared to in patients treated for severe native aortic stenosis (AS).

Methods and results: From October 2008 to January 2013, 1,557 consecutive patients undergoing CRS-TAVR, of whom 26 (1.6%) presented with AR, were prospectively followed. Compared with patients with AS, patients with AR were significantly younger (mean age 73±10 vs. 82±6, p=0.02), more frequently in NYHA Class III/IV (95% vs. 73%, p=0.01) and had a higher incidence of severe pulmonary hypertension (sPAP >60 mmHg, 31% vs. 10%, p=0.007). Log EuroSCORE and STS score were similar. VARC-2-defined device success was lower in the AR group (79% vs. 96%, p=0.006). At one month, patients treated for AR had a higher overall mortality (23% vs. 5.9%; OR 4.22 [3.03-8.28], p<0.001) and cardiac mortality (15.3% vs. 4%, OR 4.01 [2.40-7.66], p<0.001). Results were consistent at 12 months: overall mortality (31% vs. 19%, HR 2.1 [1.5-4.41], p<0.001) and cardiac mortality (19.2% vs. 6%, HR 3.1 [2.09-8.22], p<0.001).

Conclusions: CRS-TAVR for AR is associated with a significantly higher mortality compared to CRS-TAVR for AS. Considering the ominous prognosis of these patients when treated medically, TAVR may be a reasonable choice in selected patients. In this regard, conventional risk scores have an inadequate predictive value.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

aortic regurgitationtranscatheter aortic valve replacement
Read next article
Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation

Latest news